Galderma acquires skincare brand Alastin
Galderma is to add skincare brand Alastin to its portfolio of aesthetics brands.
The dermatology company has signed a definitive agreement to acquire Alastin Skincare. The medical-grade skincare brand is prescribed by cosmetic doctors and dermatologists in the US.
Founded in 2015, its products include patented TriHex technology, a proprietary blend of peptides and active botanicals to help rejuvenate skin.
Since inception, Alastin achieved a CAGR (compound annual growth rate) of 106% to 2020, while a report by Kline Group cited Alastin as the fastest growing brand in the US professional skincare market in 2020.
"… The addition of Alastin, with its synergistic portfolio and expertise in science-proven skincare, increases our ability to serve the needs of consumers and underscores our commitment to be the partner of choice for aesthetic professionals, said Flemming Ørnskov, chief executive of Galderma.
“This transaction will further enhance our premium product offering and provides a tremendous platform for future growth. We look forward to welcoming the Alastin team into Galderma and partnering with them to advance the science of dermatology together."
Galderma plans to leverage Alastin’s “global reach and integrated dermatology platform” to push forward with the brand’s next growth phase to reach more consumers via more healthcare professionals. This will include further product development and skincare technology innovation.